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Background: Tyrosine kinase inhibitors (TKIs) are currently approved for the treatment of metastatic renal cell
carcinoma (mRCC). The cardiotoxic effects of sorafenib and sunitinib may cause hypertension, left ventricular
ejection fraction (LVEF) dysfunction and/or congestive heart failure (CHF), and arterial thrombo-embolic events
(ATE). Only three cases of coronary artery disease related to sorafenib therapy have been described in the literature,
and all were due to arterial vasospasm without evidence of coronary artery stenosis on angiography. Cardiotoxicity
is commonly associated with the presence of cardiovascular risk factors, such as a history of hypertension or
coronary artery disease.
Case presentation: We describe a patient who experienced an unusual cardiac event after 2 years of sorafenib
treatment. A 58-year-old man with mRCC developed acute coronary syndrome (ischemia/infarction) associated with
critical sub-occlusion of the common trunk of the left coronary artery and some of its branches, which was
documented on coronary angiography. The patient underwent triple coronary artery bypass surgery, and sorafenib
treatment was discontinued. He did not have any cardiovascular risk factors, and his cardiac function and
morphology were normal prior to sorafenib treatment.
Conclusions: Further investigation of a larger patient population is needed to better understand cardiac damage
due to TKI treatment. Understanding the usefulness of careful cardiovascular monitoring might be important for the
prevention of fatal cardiovascular events, and to avoid discontinuation of therapy for the underlying cancer.
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Tyrosine kinase inhibitors (TKIs) are currently approved
for the treatment of metastatic renal cell carcinoma
(mRCC) [1,2]. Common toxicities due to sorafenib and
sunitinib treatment include reversible skin rashes, hand-
foot skin reaction, diarrhea, hypertension, hemorrhage,
and laboratory findings such as leucopenia, hypophospha-
temia, elevated pancreatic enzymes levels, and proteinuria
[3,4]. Other clinical events related to cardiotoxicity include
left ventricular ejection fraction (LVEF) dysfunction and/
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reproduction in any medium, provided the orembolic events (ATE) [3–8]. Several authors have con-
cluded that LVEF dysfunction and/or CHF is more fre-
quent in patients with a history of hypertension or
coronary artery disease. Only three cases of coronary ar-
tery disease related to sorafenib treatment have been
described in the literature. All three cases were associated
with the presence of cardiovascular risk factors and were
due to arterial vasospasm without evidence of coronary ar-
tery stenosis on angiography [9–11].Case presentation
In 2007, a 58-year-old white male with no history of
tobacco use, hypertension, diabetes, or hypercholesterol-
emia, and no family history of coronary artery disease,
was found to have a large solid right renal mass andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Coronary angiography showing critical sub-total
occlusion of the common trunk of the left coronary artery and
circumflex artery.
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right atrium. He underwent right radical nephrectomy
and tumor thrombectomy performed under extracorpor-
eal circulation. Cardiac function was investigated, in-
cluding coronary angiography and transthoracic and
transesophageal echocardiography. These studies docu-
mented normal cardiac function and normal morph-
ology of the coronary arteries. Pathological examination
of the surgical specimens demonstrated pT3cN0Mx con-
ventional (clear cell) renal carcinoma, Fuhrman Grade 3
with negative surgical margins. A regular follow-up pro-
gram was started. A few months later, hepatic and
contralateral renal metastases were detected. The patient
started treatment with the tyrosine kinase inhibitor
(TKI) sorafenib on a dose-escalation protocol. Treat-
ment led to an initial partial response followed by stable
disease for 6 months. During December 2008, in a set-
ting of stable disease, he underwent hepatic resection
and enucleation of the left renal mass. The hepatic and
renal masses were confirmed to be metastases. Early
radiological assessment after surgery showed no residual
hepatic or renal disease, but possible involvement of the
mesenteric lymph nodes. Sorafenib treatment was there-
fore restarted at a standard dose of 800 mg/day. Treat-
ment led to complete disease response within a few
months, and was very well tolerated by the patient, who
did not experience any of the typical adverse effects of
the drug.
During February 2011, after 30 months of sorafenib
treatment (6 months at 1600 mg/day and 24 months at
800 mg/day), the patient started to complain of worsen-
ing chest pain precipitated by normal physical exercise.
A cardiac stress test showed exercise-induced ischemia.
Coronary angiography showed critical sub-occlusion of
the common trunk of the left coronary artery and the
circumflex artery (Figure 1). The patient subsequently
underwent triple coronary artery bypass surgery and is
now recovering and in good clinical condition. Sorafenib
treatment has been discontinued.
Discussion
TKIs are currently approved for the treatment of mRCC
[1,2]. Sorafenib is a multikinase inhibitor, with activity
against transmembrane KIT, FLT-3, VEGFR-2, VEGFR-3,
and PDGFR-B receptors, and intracellular CRAF and
BRAF receptors. These kinases are involved in several
angiogenesis systems and intracellular signaling pathways,
and their disruption is aimed at inhibiting tumor growth
[12]. The clinical efficacy of Sorafenib in the treatment of
mRCC was demonstrated in a randomized, double-blind,
placebo-controlled, phase III trial (TARGET) involving
903 patients who were resistant to previous therapy. An
interim planned analysis of progression-free survival (PFS)
showed a statistically significant benefit of sorafenibtreatment over placebo (5.5 vs 2.8 months, p< 0.001).
Consequently, a crossover was permitted from placebo to
sorafenib. The difference in overall survival time was not
statistically significant (19.3 vs 15.9 months), which can be
explained by an important crossover effect. There was,
however, a 28% reduction in the risk of death in patients
receiving sorafenib [5,13]. Sorafenib may also be a suitable
alternative treatment for selected naïve patients with
clear cell mRCC [3]. A recent multicenter retrospective
analysis of sequential treatment with sorafenib and suni-
tinib showed that initial treatment with either agent was
associated with similar PFS times during first-line treat-
ment (median PFS 8.4 months with sorafenib vs
7.8 months with sunitinib; p = 0.758). However, patients
treated with sorafenib and then sunitinib appeared to
have a slightly longer PFS times during second-line treat-
ment than those treated with sunitinib and then sorafe-
nib (median PFS with second TKI: 7.9 months vs
4.2 months; p< 0.001) [14].
Common toxicities due to sorafenib treatment include
reversible skin rashes, hand-foot skin reaction, diarrhea,
hemorrhage, hypertension, and laboratory findings such
as leucopenia, hypophosphatemia, and elevated pancre-
atic enzyme levels [3,4]. Previous reports suggest that
cardiotoxicity is a rare side-effect of sorafenib [4,5].
Some studies have commented on the cardiovascular
toxicity of TKIs and monoclonal antibodies, in particular
tumor angiogenesis inhibitors [6–8,15–18] (Table 1).
The clinical events associated with cardiotoxicity include
hypertension (8-45 % overall; 4-16 % grades 3 or 4) [3],
Table 1 Data describing the main cardiotoxic events reported in clinical trials of tumor angiogenesis inhibitors
Reference Drug N of pts Events Types of events
Ranpura V et al. [6]
Meta-analysis of 20 RCTs
Bevacizumab in pts
with a variety of
advanced solid tumors
1853 61 (3.3 %) ATE (all-grade)
5558 111 (2.0 %) ATE (high-grade)
2322 34 (1.5 %) Cardiac ischemia
Richards CJ et al. [7] Sunitinib 6936 186 (4.1 %) Congestive heart failure
Choueiri TK et al. [8]
Meta-analysis of 10 studies
Sunitinb and Sorafenib
in pts with advanced
cancer
9837 122 (1.4 %)
1.3 % for Sunitinib;
1.7 % for Sorafenib (NS)
ATE
Chu TF et al. [15] Sunitinib in pts
affected
by GIST
75
36
75
8 (11 %)
6 (8 %)
10 (28 %)
7 (19 %)
35 (47 %)
Cardiovascular events
Congestive heart failure
LVEF reduction (at least 10 %)
LVEF reduction (15 % or more)
Hypertension
Telli ML et al. [16] Sunitinib in pts affected
by mRCC and GIST
48 7 (15 %) Heart failure
Di Lorenzo G et al. [17] Sunitinib in pts
affected by mRCC
175 66 (37.7 %)
17 (9.7 %)
12 (6.9 %)
33 (18.9 %) of which
12 (6.9 %)
Hypertension G1-2
Hypertension G3
LVEF dysfunction
Cardiac abnormalities
LVEF G3 and/or Congestive heart failure
Schmidinger M et al. [18] Sunitinib (Su)
and Sorafenib (So)
in pts with mRCC
74 25 [11 in Su; 14 in So] (33.8 %) of which:
12 (16.2 %)
13 (17.6 %) of which
7 (9.4 %)
Cardiac event
Biochemical signs and ECG
changes only
Clinical symptoms (angina,
dyspnea, dizziness)
Life-threatening clinical
symptoms
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ATEs (3.3 % overall; 2 % high-grade with bevacizumab
and 1.4 % high-grade with sunitinib and sorafenib) [6,8].
Several authors have concluded that LVEF dysfunction
and/or CHF is more frequent in patients with a history
of hypertension or coronary artery disease than those
without, even though a careful cardiac assessment at
baseline was not always reported.
The molecular mechanisms of TKI cardiotoxicity have
not been extensively investigated, but seem to be related
to the inhibition of kinases that have a crucial role in nor-
mal cardiovascular development [19]. The role of BRAF in
the heart is not well understood. RAF1 seems to inhibit
two pro-apoptotic kinases with ERK-independent effects:
apoptosis signal-regulating kinase 1 (ASK1) and mamma-
lian sterile 20 kinase 2 (MST2), which are both involved in
oxidant stress-induced injury. If sorafenib disrupts the
RAF1–ASK1 and/or RAF1–MST2 interactions, cardio-
toxicity might be an even greater concern than if only the
ERK cascade is inhibited [20]. To examine the in vivo role
of Raf-1 in the heart, Yamaguchy et al. generated cardiac
muscle–specific Raf-1–knockout (Raf CKO) mice with
Cre-loxP–mediated recombination [21]. The mice demon-
strated left ventricular systolic dysfunction and heart dila-
tation, related to a significant increase in the number of
apoptotic cardiomyocytes and fibrosis. The molecular
mechanism of ATE has not been well investigated, but it
seems to depend on multiple actions of VEGF on vascular
walls, and maybe also on components of the coagulationcascade. VEGF stimulates endothelial cell proliferation and
promotes endothelial cell survival, thereby helping to main-
tain vascular integrity. VEGF-signaling inhibition leads to a
decrease in the regenerative capacity of endothelial cells,
and causes cell wall defects that expose pro-coagulant
phospholipids on the luminal plasma membrane or un-
cover the matrix, favoring thrombosis. VEGF-inhibitors
may also inhibit nitric oxide and prostacyclin, increase
endothelial cell apoptosis, and promote pro-coagulant
changes and proliferation of vascular smooth muscle cells.
Finally, VEGF-inhibitors may increase the risk of ATE by
increasing the hematocrit and blood viscosity via overpro-
duction of erythropoietin [3,22].
The absence of cardiovascular risk factors or any per-
sonal or family history of cardiac disease in our patient
increases the suspicion of a correlation between his car-
diovascular disease and sorafenib treatment. His cardiac
function had been investigated and found to be normal
before starting sorafenib, because his primary surgery was
performed under extracorporeal circulation. He did not
develop hypertension (average blood pressure before and
during treatment: 125/80 mmHg) or other risk factors
during sorafenib treatment (blood glucose level about
86 mg/dl, total cholesterol level about 141 mg/dl, HDL
cholesterol level about 53 mg/dl, LDL cholesterol level
about 75 mg/dl, and triglyceride level about 90 mg/dl). He
therefore developed at least two critical sub-occlusive
lesions during the 30 months after the start of treatment,
which is a very short time period, considering the usual
Table 2 Descriptions of the three reported cases which developed coronary artery disease during sorafenib treatment
Reference Case Disease Types of events Cardiovascolar risck factors Coronarography
Naib T et al. [9] 57 years-old patient HCC multiple coronary vasospasm history of diabetes, hyperlipidemia,
former tobacco use
Normal
Arima Y et al. [10] 65 years-old patient mRCC coronary artery spasm arterial hypertension Normal
Porto I et al. [11] 63 years-old patient HCC variant angina for spontaneous
coronary spasm
history of diabetes and arterial
hypertension,
Normal
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old man without cardiovascular risk factors. The risks of
cardiac ischemia/infarction during treatment with angio-
genesis inhibitors or TKIs are reported to be very low
(1.5 % for bevacizumab, <1 % for sunitinib, 2.9 % for sora-
fenib) [6,18,23]. These events are usually associated with
the presence of cardiovascular risk factors, but few
detailed data on coronary angiography findings have been
reported. Coronary angiography was performed and found
to be normal in 7 of 74 patients with symptomatic cardiac
events [18]. The frequency of treatment for acute cardiac
ischemia was reported to be higher in patients receiving
sorafenib (2.9 %) than patients receiving placebo (0.4 %),
with an overall low rate of acute cardiac events during a
median follow-up time of 16 months [5,13]. In the
Advanced RCC Sorafenib (ARCCS) expanded access pro-
gram, ATE events, including cardiac ischemia, were not
reported [4]. Three cases of coronary artery disease related
to sorafenib therapy have been described in the literature,
which were all due to arterial vasospasm without evidence
of coronary artery stenosis on angiography, and were all
associated with cardiovascular risk factors [9–11]. Details
of these three cases are presented in Table 2.
The case presented here indicates that attention
should be paid to the potential occurrence of occlusive
coronary artery disease during treatment with TKIs,
and that patients should be carefully monitored for
the development of symptoms of coronary ischemia/
infarction. Even though cardiotoxicity is widely reported
and recognized as an important though not frequent toxic
effect of treatment with sunitinib and other tumor angio-
genesis inhibitors, there is currently no consensus regard-
ing the prevention and management of these side effects.
Conclusions
In conclusion, we have presented a brief overview of the
available data on cardiovascular events in patients treated
with TKIs, and of the potential for the development of oc-
clusive coronary artery disease. Understanding the useful-
ness of careful cardiovascular monitoring might be
important to prevent fatal cardiovascular events and avoid
discontinuation of treatment for the underlying cancer.
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